8JCL

The crystal structure of SARS-CoV-2 main protease in complex with Compound 52

8JCL の概要

• エントリーDOI: 10.2210/pdb8jcl/pdb
• 分子名称: 3C-like proteinase nsp5, 3-ethanoyl-N-phenyl-benzamide, HYDROSULFURIC ACID, ... (4 entities in total)
• 機能のキーワード: sars-cov-2, main protease, 3clpro, mpro, viral protease, compound 52, hydrolase
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 34098.90

構造登録者

Zhao, Y.,Zhu, Y.,Rao, Z. (登録日: 2023-05-11, 公開日: 2024-05-15, 最終更新日: 2025-05-28)

主引用文献

Zhu, Y.,Meng, J.,Feng, B.,Zhao, Y.,Zang, Y.,Lu, L.,Su, M.,Yang, Q.,Zhang, Q.,Feng, L.,Zhao, J.,Shao, M.,Ma, Y.,Yang, X.,Yang, H.,Li, J.,Jiang, X.,Rao, Z.
De novo design of SARS-CoV-2 main protease inhibitors with characteristic binding modes.
Structure, 32:1327-1334.e3, 2024

PubMed Abstract: The coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which spreads rapidly all over the world. The main protease (M) is significant to the replication and transcription of viruses, making it an attractive drug target against coronaviruses. Here, we introduce a series of novel inhibitors which are designed de novo through structure-based drug design approach that have great potential to inhibit SARS-CoV-2 Min vitro. High-resolution structures show that these inhibitors form covalent bonds with the catalytic cysteine through the novel dibromomethyl ketone (DBMK) as a reactive warhead. At the same time, the designed phenyl group beside the DBMK warhead inserts into the cleft between H41 and C145 through π-π stacking interaction, splitting the catalytic dyad and disrupting proton transfer. This unique binding model provides novel clues for the cysteine protease inhibitor development of SARS-CoV-2 as well as other pathogens.

PubMed: 38925121
DOI: 10.1016/j.str.2024.05.019

実験手法

X-RAY DIFFRACTION (1.59 Å)